Vitrolife A/S

Gothenburg, Sweden All Sweden companies → — Founded 1994

Medical Device / Hardware Point-of-Care Diagnostics Specialty-Focused AI

Obstetrics & Gynecology

Lab & Diagnostics OB/GYN AI

Publicly Traded — $300M

Claim this company

Products

KIDScore D3

Vitrolife A/S

Lab & Diagnostics

KIDScore D3 by Vitrolife A/S is an AI-based decision support tool for Day 3 embryo selection in IVF, providing a morphokinetic score to aid embryologists in identifying embryos with the highest implantation potential.

Contact for pricing

See all 1 product →

About Vitrolife A/S

Vitrolife A/S, part of the Vitrolife Group, is a global leader in reproductive health, dedicated to supporting fertility clinics and patients worldwide to improve treatment outcomes. Since its founding in 1994, the company has focused on developing, manufacturing, and distributing a comprehensive portfolio of medical devices and genetic testing services for the entire reproductive-health journey. This includes high-quality culture media for oocyte and embryo development, cryopreservation solutions, and instruments for various IVF procedures such as oocyte retrieval and embryo transfer.

The Vitrolife Group leverages advanced research and innovation, with a significant focus on integrating cutting-edge technologies like artificial intelligence (AI) into its offerings. For instance, its iDAScore® is an AI-based scoring system that provides fully automated analysis of time-lapse sequences from embryo development, aiming to objectively rank embryos for selection and potentially shorten the time to pregnancy. The company also invests in early-stage MedTech companies like AutoIVF, which is developing automated systems to simplify and decentralize egg retrieval and preparation, further enhancing accessibility and efficiency in fertility care. Through these efforts, Vitrolife aims to optimize clinical workflows, standardize procedures, and deliver consistent, high-quality solutions to meet the evolving needs of the fertility market.

Focus Areas

Reproductive health Assisted Reproductive Technology (ART) In Vitro Fertilization (IVF) genetic testing embryo assessment time-lapse technology AI technology automation digitalization medical devices culture media cryopreservation solutions instruments

Business Intelligence

Key Investors	William Demant Invest A/S, Bure Equity AB, J.P. Morgan, Morgan Stanley, Alpha Edison
Partnerships	Virtus Health, Harrison.AI, AutoIVF
Acquisitions	eFertility (May 2024), Igenomix (July 2021), Octax Microscience (June 2016), FertiliTech A/S (November 2014), Cryo Innovation (June 2012), HertART Aps (2010), Conception Technologies (2013), Swemed Lab
Technology	End-to-end platform for IVF workflow automation, standardization, and digitalization; utilizes deep learning and neural networks for AI-based imaging analysis tools with time-lapse incubators (e.g., EmbryoScope)
FDA Clearances	38 cleared products (estimated)

What Physicians Need to Know

Reproductive Health & ART Solutions

Vitrolife offers a comprehensive product portfolio covering the entire Assisted Reproductive Technology (ART) and In Vitro Fertilization (IVF) journey, from oocyte retrieval to embryo transfer, aiming to improve patient treatment outcomes.

Genetic Testing & Diagnostics

Pioneering genetic testing solutions, significantly enhanced by the acquisition of Igenomix, provide services for preconception, pre-implantation (PGT-A), and prenatal phases, including Genomics kits for laboratory use.

Embryo Assessment & Selection

Advanced software tools, including AI-based algorithms like iDAScore and KIDScore (D3, D5), and Guided Annotation, offer objective embryo evaluation and selection based on morphological and morphokinetic parameters, aiding in implantation likelihood assessment.

Time-Lapse Technology

Vitrolife pioneered time-lapse systems, such as EmbryoScope and EmbryoScope+, for continuous, undisturbed embryo monitoring, which improves embryo selection, optimizes laboratory workflows, and enhances patient communication.

AI & Automation in IVF

Utilizes AI for embryo assessment (iDAScore, Guided Annotation) and focuses on automation and workflow efficiency through integrated solutions like the eWitness system for secure, error-free tracking, and the acquired eFertility cloud-based practice management software.

Medical Devices & Instruments

A global provider of high-quality medical devices for IVF clinics, including oocyte retrieval needles, versatile micro-laser platforms for assisted hatching and biopsies, and cryopreservation devices.

Culture Media & Cryopreservation

A pioneer in delivering high-quality, ready-to-use culture media for IVF laboratories, setting industry standards for quality control and consistency for over two decades. They also provide comprehensive cryopreservation solutions.

Physician Tip

For physicians, Vitrolife stands out by offering an integrated ecosystem of high-quality products and advanced technologies that cover the entire IVF journey. Their commitment to scientific rigor and stringent quality control ensures reliable and consistent product performance, minimizing variability in clinical outcomes. The AI-powered embryo assessment tools (iDAScore, KIDScore) and time-lapse systems (EmbryoScope) provide objective data and enhanced decision support for embryo selection, potentially leading to improved implantation rates and better patient outcomes. Furthermore, their focus on workflow efficiency through automation (eWitness) and comprehensive clinical and scientific support, including a global network of embryologists and genetic counselors via the Vitrolife Academy, empowers clinics to optimize their operations and provide superior patient care. The ability to offer pioneering genetic testing solutions (Igenomix) allows for a more holistic approach to patient diagnosis and treatment across different reproductive stages.

Vitrolife's technology stack is designed for integration within the IVF laboratory workflow. Their time-lapse systems are built to seamlessly monitor embryos in an undisturbed culture environment. The AI-driven assessment tools (iDAScore, Guided Annotation) integrate with these systems to provide automated analysis and decision support. The eWitness system offers secure, error-free tracking across the IVF journey, and the acquisition of eFertility indicates a move towards integrating practice management software. Vitrolife also collaborates with external partners and offers customized support to adapt products to unique laboratory needs.

At a glance

Founded 1994

HQ Gothenburg, Sweden · Sweden

Team size ~1,100-1,150

CEO Bronwyn Brophy O'Connor

Funding Publicly Traded — $300M

FDA clearances 38 (estimated)

Products 1

Products by Vitrolife A/S

1 product in the directory

KIDScore D3

Vitrolife A/S

Lab & Diagnostics

Contact for pricing

What the Web Says

Vitrolife A/S is a global company specializing in products for In Vitro Fertilization (IVF), aiming to support successful treatment outcomes and help couples achieve parenthood. They offer a comprehensive portfolio of IVF media and labware, emphasizing quality, consistency, and scientific precision in their products. Employee reviews indicate a mixed sentiment, with some highlighting a supportive environment and good benefits, while others point to issues with management and a toxic work culture.

Overall: Mixed

Strengths

Products are of high quality, reliable, and extensively tested for IVF procedures.
Products are designed to simplify and improve daily work in the lab, offering a secure environment for gametes and embryos.
Vitrolife media, such as G-Series, have shown to improve embryo development and clinical outcomes.
The company offers good benefits and opportunities for management and sales training.
Some employees report a supportive environment, great coworkers, and a clear sense of purpose.
The company is committed to fostering a positive and inclusive work environment.

Limitations

Some employees describe a poorly managed and toxic work environment.
There are concerns about high turnover due to poor morale and a lack of management experience.
Issues with job security and advancement are noted by some employees.
Some reviews mention a lack of clear company goals, no accountability, and minimal recognition for hard work.
Employees in production may experience long and unpredictable work hours.
There are mentions of gossip, rumors, and bullying, especially towards new employees.

Based on reviews from: Indeed.com, SimplyHired, Shortlister, IVF Store, Vitrolife.com, YouTube, Reddit

Last updated: 2026-07-20

Videos

News, demos, and interviews about Vitrolife A/S.

Loading videos...

Videos load interactively. If none appear, search YouTube for Vitrolife A/S →

View all on YouTube

Press & Coverage

Vitrolife Group

Interim report Q2, 2026: Strong margins and high profitability in soft market conditions

Vitrolife Group released its Q2 2026 interim report, highlighting strong margins and profitability despite soft market conditions, driven by portfolio rationalization, cost control, and strategic pricing. The company also announced a SEK 500 million share repurchase program.

2026-07

Vitrolife Group

Vitrolife Group launches SEK 500 million share repurchase programme

Vitrolife Group's Board of Directors has resolved to launch a share repurchase program of up to SEK 500 million, running from July 17, 2026, until the next Annual General Meeting, to optimize the company's capital structure and increase shareholder value. This program is in addition to the ordinary cash dividend for the 2025 financial year.

2026-07

Investing.com

Vitrolife Q2 2026 slides: margins surge amid revenue headwinds

Vitrolife Group's Q2 2026 results show a strategic shift towards profitability over volume growth, with net sales of SEK 857 million and substantial margin expansion across all business segments. The company's stock surged over 10% following the announcement of improved profitability and the share repurchase program.

2026-07

MarketScreener

Capital Group flags stake below 5 percent in Vitrolife

Asset manager Capital Group has reduced its holding in Vitrolife, crossing the 5 percent disclosure threshold. Following a sale on July 16, their holding now represents 4.77 percent of the shares and votes, making them the fifth-largest shareholder.

2026-07

MarketScreener

Vitrolife increased operating profit more than expected

Vitrolife reported Q2 2026 revenue slightly below expectations but operating profit that exceeded forecasts, driven by strong margins and profitability from portfolio rationalization, cost control, and strategic pricing.

2026-07

PR Newswire (via Cision News)

Vitrolife announces genetic services restructuring program targeting annualised savings of 65 MSEK and recognises a 5.4 BSEK goodwill impairment

Vitrolife announced a restructuring program for its genetic services business, aiming for SEK 65 million in annual savings by Q3 2026, and will record a SEK 5.4 billion goodwill impairment in Q4 2025 related to the Igenomix acquisition. The program includes discontinuing two genetic test lines (GPDx and NACE).

2025-12

accessdata.fda.gov

K243373 - accessdata.fda.gov

The FDA issued a 510(k) clearance for Vitrolife's Embryo Transfer Catheter, intended for the introduction of in vitro fertilized embryos into the uterine cavity. The clearance also covers the use of a stylet to assist in uterine access during the procedure.

2025-07

eFertility

Press release: Vitrolife AB (publ) acquires eFertility

Vitrolife AB acquired 100% of the shares in eFertility, an innovative system and software company specializing in IVF clinic management solutions like eWitness and eBase. This acquisition is a key step in Vitrolife Group's strategy to standardize and digitalize the IVF patient journey.

2024-05

Frequently Asked Questions

What range of products does Vitrolife A/S offer to support the entire Assisted Reproductive Technology (ART) workflow, from oocyte retrieval to embryo transfer and cryopreservation?

Vitrolife A/S provides a comprehensive portfolio of medical devices and genetic testing services that cover the entire reproductive health journey. Their offerings span the IVF workflow, including oocyte retrieval needles, sperm preparation media, embryo culture media (like G-TL), embryo transfer media (such as EmbryoGlue), and cryopreservation solutions and devices.

How does Vitrolife A/S integrate advanced technologies like time-lapse imaging and AI into their embryo assessment tools to improve IVF success rates?

Vitrolife A/S integrates time-lapse technology, such as the EmbryoScope+ system, for continuous and undisturbed embryo monitoring. They utilize AI-based tools like iDAScore and Guided Annotation to provide objective embryo ranking based on implantation likelihood, which streamlines evaluation and enhances embryo selection for improved IVF outcomes.

What are Vitrolife A/S's offerings related to genetic testing in ART, and how do they ensure compliance with relevant regulatory standards for their medical devices and solutions?

Through the acquisition of Igenomix, Vitrolife Group offers a complete genetic testing portfolio for reproductive health professionals, including pioneering tests for various stages of the reproductive journey. They ensure compliance by classifying products as medical devices, adhering to international regulatory standards like CE mark, FDA-clearance, and TGA-approval, and maintaining quality accreditations for genetic laboratories such as CLIA.

How does Vitrolife A/S support clinics in adopting automation and digitalization within their IVF labs, and what kind of technical support and training do they provide?

Vitrolife A/S supports automation and digitalization with solutions like eWitness and EmbryoScope integration, which automate patient registration and synchronize data to create streamlined, error-free, and audit-ready lab workflows. They offer extensive clinical and scientific support globally through a network of embryologists and genetic counselors, providing education and training via platforms like Vitrolife Academy to optimize IVF processes.

What is Vitrolife A/S's market position and company stability, and what opportunities exist for partnerships or collaborations with healthcare providers?

Vitrolife Group is a world-leading global provider of medical devices and genetic testing services in reproductive health, with over three decades of innovation and a strong presence in more than 125 markets. They actively collaborate with universities and clinics for research and development, positioning themselves as a trusted partner for healthcare providers seeking to improve patient outcomes through quality and innovation.

Can you provide insight into the pricing structure and cost-effectiveness of Vitrolife A/S's solutions, particularly for high-volume IVF centers?

While specific pricing details are not publicly available, Vitrolife's solutions are designed to enhance workflow efficiency, reduce manual workload through automation, and improve embryo selection with advanced time-lapse and AI technologies. These efficiencies contribute to cost-effectiveness for high-volume IVF centers by aiming for better patient outcomes and potentially reducing overall treatment costs per successful pregnancy.

What specific medical devices and instruments does Vitrolife A/S provide for IVF procedures, and how do they ensure their quality and reliability?

Vitrolife A/S offers various medical devices and instruments for IVF, including oocyte retrieval needles (e.g., Sense), embryo transfer catheters, micro-laser platforms for techniques like assisted hatching, and time-lapse incubators such as EmbryoScope+. They ensure quality and reliability through a comprehensive quality control program, extensive testing that exceeds regulatory demands, and adherence to medical device directives (e.g., CE mark, FDA-clearance), guaranteeing safe, non-toxic, and consistently high-quality products.

What are Vitrolife A/S's current R&D priorities and future innovations planned for the reproductive health sector?

Vitrolife A/S's R&D priorities include continuous improvement of existing products and the development of new offerings in their state-of-the-art laboratories, often in collaboration with external universities and clinics. Future innovations focus on advancing AI, automation, genetic screening, and data analytics to enable more personalized, efficient, and accessible IVF treatments, with a strategic vision to create a connected platform across the entire IVF workflow.

Related Companies

Suggest an Edit →